



ASX ANNOUNCEMENT

6 March 2025

January 2025 Investor Presentation: Clarification and Retraction

Following recent discussions with the ASX, **Opyl Limited (ASX: OPL) (the Company)** wishes to make the following clarifications and retractions in respect of its ASX release titled "*Investor Presentation – January 2025*" released on 30 January 2025 (**the Presentation**):

- Page 2 of the Presentation referred to a potential revenue figure which would result if TrialKey were to provide reports to 65,000 trials (126,007 reports). This was not, nor intended to be, a revenue forecast rather a statement which quantified the total addressable market for TrialKey. The Company will not solely address the total addressable market for TrialKey and is not in a position to forecast the percentage, if any, of that market it will access. This statement is retracted in full from the Presentation.
- Page 7 of the Presentation, which referred to an "*Example Simulation*", noted a "*Potential client saving \$7M*" in respect of that example simulation. This was not, nor intended to be, a financial forecast rather an example of savings that might be achieved on a hypothetical trial (on assumptions of reduced participation costs and a reasonable assumption of those costs). This statement is retracted in full from the Presentation.
- Page 14 of the Presentation identified sales targets for years 1-3. Those sales targets reflect the contracted minimum targets required for the Company's partner to retain exclusivity in their markets in respect of the TrialKey product. The sales targets are not guaranteed and are not, and not intended to be, revenue forecasts.
- Page 15 of the Presentation included revenue targets. Those targets were based on the minimum sales targets referred to above. As noted above, those sales targets are not guaranteed.
- Page 19 of the Presentation included a statement of target revenues for the period between 2025-2027. This statement is retracted in full from the Presentation.
- Page 22 of the Presentation expressed an 'asset under management' (**AUM**) target for the AI BioTech Fund. The AUM target is based on agreed targets with the Company's partner however is not a contractual requirement, nor guaranteed.
- Page 31 of the Presentation included targeted revenue share figures. These statements were aspirational and based, in part, on the contracted sales targets referred to above which are not guaranteed. These statements are retracted in full from the Presentation.



The Company advises that investors should not rely on the statements which are noted above as having been retracted in full from the Presentation. The Company does not consider those statements to be forecasts (financial or otherwise), and investors should not interpret them as forecasts. Under ASIC policies, any forecast is required to be made only on reasonable grounds which, in the case of financial forecasts, by way of example, would include a track record of financial performance. If the Company makes forecasts in the future, it will only do so where such grounds exist.

This announcement has been authorised for release by the board

-ENDS-

For investor enquiries:

Bernice Averion
Head of Marketing and Communications
Phone: +61 415 311 957
Email: bernice@trialkey.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions